Yikyung Kim1, Hwan-Ho Cho2,3, Sung Tae Kim1, Hyunjin Park4,5, Dohyun Nam6, Doo-Sik Kong6. 1. Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, South Korea. 2. Department of Electrical and Computer Engineering, Sungkyunkwan University, Suwon, South Korea. 3. Center for Neuroscience Imaging Research, Institute for Basic Science, 16419, Suwon, South Korea. 4. Center for Neuroscience Imaging Research, Institute for Basic Science, 16419, Suwon, South Korea. hyunjinp@skku.edu. 5. School of Electronic and Electrical Engineering, Sungkyunkwan University, 16419, Suwon, South Korea. hyunjinp@skku.edu. 6. Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Abstract
PURPOSE: To determine the feasibility of using high dimensional computer-extracted features, known as radiomics features, in differentiating primary central nervous system lymphoma (PCNSL) from glioblastoma on multi-parametric MR imaging including diffusion-weighted imaging. METHODS: Retrospective evaluation of data was approved by the local ethics committee and informed consent was waived. A total of 143 patients (two independent cohorts for discovery [n = 86; glioblastoma = 49, PCNSL = 37] and validation [n = 57; glioblastoma = 29, PCNSL = 28]) with newly diagnosed glioblastoma and PCNSL were subjected to radiomics analysis using the multi-parametric MRI (contrast-enhanced T1-weighted imaging, T2-weighted imaging, and diffusion-weighted imaging). Radiomics analyses were performed for two types of regions of interest (ROI) covering contrast-enhancing tumor and whole (enhancing or non-enhancing) tumor plus peritumoral edema. A total of 127 radiomics features were calculated. Feature selection was performed to identify the most discriminating features for every MR image in the discovery cohort. The identified features were used to calculate radiomics scores, which were later used in logistic regression to distinguish between PCNSL and glioblastoma. The classification model was further tested on the independent validation cohort. RESULTS: Fifteen features were selected as significant features in the discovery cohort. Using the identified features and calculated radiomics scores, the logistic regression-based classifier yielded an area under the curve (AUC) of 0.979, sensitivity of 0.938, and specificity of 0.944 in the discovery cohort to distinguish between glioblastoma and PCNSL. A similarly high rate of performance was observed in the validation cohort (AUC = 0.956). CONCLUSIONS: Radiomics features derived from multi-parametric MRI can be used to differentiate PCNSL from glioblastoma effectively.
PURPOSE: To determine the feasibility of using high dimensional computer-extracted features, known as radiomics features, in differentiating primary central nervous system lymphoma (PCNSL) from glioblastoma on multi-parametric MR imaging including diffusion-weighted imaging. METHODS: Retrospective evaluation of data was approved by the local ethics committee and informed consent was waived. A total of 143 patients (two independent cohorts for discovery [n = 86; glioblastoma = 49, PCNSL = 37] and validation [n = 57; glioblastoma = 29, PCNSL = 28]) with newly diagnosed glioblastoma and PCNSL were subjected to radiomics analysis using the multi-parametric MRI (contrast-enhanced T1-weighted imaging, T2-weighted imaging, and diffusion-weighted imaging). Radiomics analyses were performed for two types of regions of interest (ROI) covering contrast-enhancing tumor and whole (enhancing or non-enhancing) tumor plus peritumoral edema. A total of 127 radiomics features were calculated. Feature selection was performed to identify the most discriminating features for every MR image in the discovery cohort. The identified features were used to calculate radiomics scores, which were later used in logistic regression to distinguish between PCNSL and glioblastoma. The classification model was further tested on the independent validation cohort. RESULTS: Fifteen features were selected as significant features in the discovery cohort. Using the identified features and calculated radiomics scores, the logistic regression-based classifier yielded an area under the curve (AUC) of 0.979, sensitivity of 0.938, and specificity of 0.944 in the discovery cohort to distinguish between glioblastoma and PCNSL. A similarly high rate of performance was observed in the validation cohort (AUC = 0.956). CONCLUSIONS: Radiomics features derived from multi-parametric MRI can be used to differentiate PCNSL from glioblastoma effectively.
Entities:
Keywords:
Diagnosis; Glioblastoma; Lymphoma; Machine learning; Magnetic resonance imaging
Authors: Philippe Lambin; Emmanuel Rios-Velazquez; Ralph Leijenaar; Sara Carvalho; Ruud G P M van Stiphout; Patrick Granton; Catharina M L Zegers; Robert Gillies; Ronald Boellard; André Dekker; Hugo J W L Aerts Journal: Eur J Cancer Date: 2012-01-16 Impact factor: 9.162
Authors: Riyadh N Al-Okaili; Jaroslaw Krejza; John H Woo; Ronald L Wolf; Donald M O'Rourke; Kevin D Judy; Harish Poptani; Elias R Melhem Journal: Radiology Date: 2007-05 Impact factor: 11.105
Authors: Haruka Itakura; Achal S Achrol; Lex A Mitchell; Joshua J Loya; Tiffany Liu; Erick M Westbroek; Abdullah H Feroze; Scott Rodriguez; Sebastian Echegaray; Tej D Azad; Kristen W Yeom; Sandy Napel; Daniel L Rubin; Steven D Chang; Griffith R Harsh; Olivier Gevaert Journal: Sci Transl Med Date: 2015-09-02 Impact factor: 17.956
Authors: Joost J M van Griethuysen; Andriy Fedorov; Chintan Parmar; Ahmed Hosny; Nicole Aucoin; Vivek Narayan; Regina G H Beets-Tan; Jean-Christophe Fillion-Robin; Steve Pieper; Hugo J W L Aerts Journal: Cancer Res Date: 2017-11-01 Impact factor: 12.701
Authors: G I Cassinelli Petersen; J Shatalov; T Verma; W R Brim; H Subramanian; A Brackett; R C Bahar; S Merkaj; T Zeevi; L H Staib; J Cui; A Omuro; R A Bronen; A Malhotra; M S Aboian Journal: AJNR Am J Neuroradiol Date: 2022-03-31 Impact factor: 3.825
Authors: Jeanette E Eckel-Passow; Daniel H Lachance; Paul A Decker; Thomas M Kollmeyer; Matthew L Kosel; Kristen L Drucker; Susan Slager; Margaret Wrensch; W Oliver Tobin; Robert B Jenkins Journal: Neurooncol Pract Date: 2022-03-12
Authors: Mathew Pease; Zachary C Gersey; R R Colen; P O Zinn; Murat Ak; Ahmed Elakkad; Aikaterini Kotrotsou; Serafettin Zenkin; Nabil Elshafeey; Priyadarshini Mamindla; Vinodh A Kumar; Ashok J Kumar Journal: J Neurooncol Date: 2022-10-14 Impact factor: 4.506